Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Treating cystic fibrosis: an interview with Simon Bedson, Senior Vice President and International General Manager at Vertex

Cystic fibrosis is a rare, life-shortening genetic disease for which there is no cure. It affects more than 75,000 people worldwide. In CF, thick, sticky mucus blocks the passages in many organs, leading to a variety of symptoms. In particular, mucus builds up and clogs airways in the lungs making it easier for bacteria to grow.

5 Mar 2014

Computational Fluid Dynamics helps patients with pulmonary disorders breathe easier

A more accurate and successful, yet complex approach used in designing an airplane is now taking off in the health care industry.

5 Mar 2014

Scientists find certain species of nontuberculous mycobacteria in water that cause infection in humans

Brisbane's water supply has been found to contain disease carrying bugs which can be directly linked to infections in some patients, according to a new study by QUT.

3 Mar 2014

Heat shock protein may be involved in folding processes of tau protein

Proteins like the so-called heat shock protein Hsp90 play an important role in almost all processes within human cells. They help other proteins fold into their three-dimensional structure or return damaged proteins back into their proper shape.

3 Mar 2014

Link found between pollutants and certain metabolic complications of obesity

A team of researchers at the IRCM in Montr-al led by R-mi Rabasa-Lhoret, in collaboration with J-r-me Ruzzin from the University of Bergen in Norway, found a link between a type of pollutants and certain metabolic complications of obesity. Their breakthrough, published online this week by the Journal of Clinical Endocrinology & Metabolism, could eventually help improve the prevention, diagnosis, and treatment of cardiometabolic risk associated with obesity, such as diabetes, hypertension and cardiovascular disease.

28 Feb 2014

FDA approves KALYDECO for people with cystic fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for KALYDECOTM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO was first approved in January 2012 for people with CF ages 6 and older who have at least one copy of the G551D mutation.

26 Feb 2014

Researcher identifies ''conductor'' in development of muscle tissue

A team led by Jean-Fran-ois C-t-, researcher at the IRCM, identified a ''conductor'' in the development of muscle tissue. The discovery, published online yesterday by the scientific journal Proceedings of the National Academy of Sciences (PNAS), could have an important impact on the treatment of muscular diseases such as myopathies and muscular dystrophies.

26 Feb 2014

Scientists identify lung-damaging molecule in cystic fibrosis patients during symptom flare-ups

A molecule previously linked to lung injuries in factory workers producing microwave popcorn might play an important role in microbial infections of the lung suffered by people with cystic fibrosis (CF), according to a recent study led by San Diego State postdoctoral researcher Katrine Whiteson.

25 Feb 2014

Ajoene in garlic prevents bacteria from destroying white blood cells

Aggressive multi-resistant infections constitute an increasing health problem all over the world. Bacteria are developing resistance at an alarming pace, so new pharmaceuticals that can combat this threat are in great demand.

19 Feb 2014

Forest Laboratories plans to discontinue sale of NAMENDA 5 mg and 10 mg tablets

Forest Laboratories, Inc., a leading, fully integrated, specialty pharmaceutical company largely focused on the United States market, today announced that it plans to discontinue the sale of NAMENDA (memantine HCl) 5 mg and 10 mg tablets effective August 15, 2014.

16 Feb 2014

Nearly half of HIV-infected teenagers, young adults forego treatment

Nearly half of HIV-infected teenagers and young adults forego timely treatment, delaying care until their disease has advanced, which puts them at risk for dangerous infections and long-term complications, according to a study led by the Johns Hopkins Children's Center.

4 Feb 2014

Not all children, young adults treated achieve long-term relief from symptoms of anxiety

Fewer than one in two children and young adults treated for anxiety achieve long-term relief from symptoms, according to the findings of a study by investigators from the Johns Hopkins Children's Center and five other institutions.

30 Jan 2014

Cystic Fibrosis Center receives Quality Care Award for commitment to improve quality of care in CF patients

The Cystic Fibrosis Center at Rutgers Robert Wood Johnson Medical School and Robert Wood Johnson University Hospital has been selected by the Cystic Fibrosis Foundation (CFF) for the foundation's prestigious Quality Care Award for 2012-2013.

30 Jan 2014

Forest Laboratories third quarter net sales increase 24.9% to $846.8 million

Forest Laboratories, Inc., a leading, fully integrated, specialty pharmaceutical company largely focused on the United States market, announced that reported diluted earnings per share equaled $0.07 in the third quarter of fiscal 2014, compared to a reported loss per share of ($0.58) in the third quarter of fiscal 2013. The third quarter of fiscal 2014 included a $45 million charge ($28.2 million net of tax) related to Project Rejuvenate.

21 Jan 2014

Study reveals high prevalence of TB infection among young children

A small study by investigators from the Johns Hopkins Children's Center and Byramjee Jeejeebhoy Government Medical College in India reveals high prevalence of tuberculosis infection among young children, troubling rates of disseminated disease and alarming patterns of drug resistance.

15 Jan 2014

Forest Laboratories enters into definitive agreement to acquire Aptalis

Forest Laboratories, Inc. today announced that it has entered into a definitive agreement to acquire Aptalis, a privately held U.S. based specialty Gastrointestinal and Cystic Fibrosis company, for $2.9 billion in cash from its shareholders, including TPG, the global private investment firm. The acquisition, which requires review by anti-trust authorities in the US and Canada, is expected to be accretive to Forest's FY2015 non-GAAP EPS.

8 Jan 2014

AIT initiates Phase II clinical trial of NOxCureCF for patients with cystic fibrosis

Advanced Inhalation Therapies, an Israeli drug development company, announced today that it has begun enrollment in Israel for a multicenter, open label, Phase II clinical trial of NOxCureCF, a respiratory treatment for patients with cystic fibrosis.

8 Jan 2014

FDA OOPD grants orphan drug designation to Alitair's Erdosteine for treatment of bronchiectasis

Alitair Pharmaceuticals, Inc., today announced that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation for its drug candidate, Erdosteine, for the treatment of bronchiectasis. Erdosteine is a mucolytic with antibacterial, anti-inflammatory, and antioxidant properties.

7 Jan 2014

Electromed gets FDA clearance to market next generation SmartVest Airway Clearance System

Electromed, Inc., a global medical device company, today announced it has received notification from the U.S. Food and Drug Administration that its next generation SmartVest Airway Clearance System, the model SQL has been cleared to market.

30 Dec 2013

Scientists develop new potential cure for rare eye disease

University of British Columbia and Vancouver Coastal Health scientists have developed a potential cure for a rare eye disease, showing for the first time that a drug can repair a birth defect.

22 Dec 2013

Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Treating cystic fibrosis: an interview with Simon Bedson, Senior Vice President and International General Manager at Vertex

Computational Fluid Dynamics helps patients with pulmonary disorders breathe easier

Scientists find certain species of nontuberculous mycobacteria in water that cause infection in humans

Heat shock protein may be involved in folding processes of tau protein

Link found between pollutants and certain metabolic complications of obesity

FDA approves KALYDECO for people with cystic fibrosis

Researcher identifies ''conductor'' in development of muscle tissue

Scientists identify lung-damaging molecule in cystic fibrosis patients during symptom flare-ups

Ajoene in garlic prevents bacteria from destroying white blood cells

Forest Laboratories plans to discontinue sale of NAMENDA 5 mg and 10 mg tablets

Nearly half of HIV-infected teenagers, young adults forego treatment

Not all children, young adults treated achieve long-term relief from symptoms of anxiety

Cystic Fibrosis Center receives Quality Care Award for commitment to improve quality of care in CF patients

Forest Laboratories third quarter net sales increase 24.9% to $846.8 million

Study reveals high prevalence of TB infection among young children

Forest Laboratories enters into definitive agreement to acquire Aptalis

AIT initiates Phase II clinical trial of NOxCureCF for patients with cystic fibrosis

FDA OOPD grants orphan drug designation to Alitair's Erdosteine for treatment of bronchiectasis

Electromed gets FDA clearance to market next generation SmartVest Airway Clearance System

Scientists develop new potential cure for rare eye disease

Innovation in neuroscience drug discovery - eBook eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Innovation in neuroscience drug discovery - eBook eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in